Excellent liver retransplantation outcomes in hepatitis C-infected recipients

Kressel, A., Therapondos, G., Bohorquez, H., Borg, B., Bruce, D., Carmody, I., Cohen, A., Girgrah, N., Joshi, S., Reichman, T. and Loss, G.E. (2013) Excellent liver retransplantation outcomes in hepatitis C-infected recipients. Clinical Transplantation, 27 4: E512-E520. doi:10.1111/ctr.12182

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Kressel, A.
Therapondos, G.
Bohorquez, H.
Borg, B.
Bruce, D.
Carmody, I.
Cohen, A.
Girgrah, N.
Joshi, S.
Reichman, T.
Loss, G.E.
Title Excellent liver retransplantation outcomes in hepatitis C-infected recipients
Journal name Clinical Transplantation   Check publisher's open access policy
ISSN 0902-0063
Publication date 2013-01-01
Year available 2013
Sub-type Article (original research)
DOI 10.1111/ctr.12182
Volume 27
Issue 4
Start page E512
End page E520
Total pages 9
Place of publication Malden, MA, U.S.A.
Publisher Wiley-Blackwell Publishing, Inc.
Language eng
Subject 2747 Transplantation
Abstract Survival outcomes for liver retransplantation (LRTx) after graft loss in HCV patients (HCV-LRTx) are generally considered inferior to those after non-HCV-LRTx. Between January 1, 2005 and June 30, 2011, our center performed 663 LTx, including 116 (17.5%) LRTx, 41 (35.3%) of which were more than 90 d after the LTx. Twenty-nine (70.7%) LRTx were performed in HCV antibody-positive individuals. We compared patient demographics, baseline characteristics and outcomes of our HCV-LRTx group with the HCV-LRTx patients from the most recent OPTN database covering the same time period. Our Kaplan-Meier HCV-LRTx one-, three-, and five-yr HCV-LRTx patient survival rates were 86.2%, 79.0%, and 72.4%, respectively compared with the OPTN one-, three-, and five-yr HCV-LRTx survival rates of 73.3%, 59.0%, and 51.3% respectively. Likewise, our graft survival rates were higher than OPTN rates at all time points studied. We performed a higher percentage of HCV-LRTx as simultaneous liver/kidney transplants (SLK) (37.9% vs. 21.8%) and recorded shorter warm (30 ± 4 vs. 45 ± 23 min) and cold ischemic times (5:44 ± 1:53 vs. 7:36 ± 3:12 h:min). Conclusion: In our experience, HCV-LRTx patient and graft survival rates are comparable to LTx survival rates and are higher than the rates described by OPTN.
Keyword Cold ischemic time
HCV recurrence
Survival rates
Warm ischemic time
Q-Index Code C1
Q-Index Status Confirmed Code
Grant ID 234-2005-370011C
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 09 Apr 2014, 20:51:27 EST by Matthew Lamb on behalf of School of Medicine